Brecon Pharmaceuticals joins forces with Quadramed

Published: 6-Aug-2004 Featured companies: PCI Pharma Services

UK-based pharmaceutical outsource provider Brecon Pharmaceuticals has formed a partnership with international regulatory affairs consultancy QuadraMed to offer a comprehensive clinical trials support service.


UK-based pharmaceutical outsource provider Brecon Pharmaceuticals has formed a partnership with international regulatory affairs consultancy QuadraMed to offer a comprehensive clinical trials support service.

Following the introduction of the new EU Clinical Trials Directive in May, pharmaceutical companies carrying out clinical trials have had to comply with an increasing and often confusing array of new legislation. The new specialist partnership will enable Brecon's and QuadraMed's customers to receive a comprehensive clinical trials service from a single point of contact.

'There is an increasing demand from our customers for guidance in the completion and submission of regulatory documentation, translation services or EU legal representation,' said Dr Sue Miles, Brecon's head of clinical services. 'By establishing this partnership with a specialist regulatory affairs consultancy, we can now offer our customers a specialist and comprehensive service.'

  

Featured companies

PCI Pharma Services: Your bridge between life-changing therapies and patients.
See more

You may also like

Drug Delivery

Breaking barriers: enhancing the bioavailability of orally delivered TPDs

Read more
It’s been said that nothing vast enters the realm of mortals without a curse. Such is the case with targeted protein degraders (TPDs), now one of the fastest-growing frontiers in oral solid dose pharmaceuticals

Trending Articles

  1. Continuous innovation: redefining the future of pharmaceutical manufacturing In an industry in which reliability is paramount and change can be slow, GEA has consistently proven that innovation and stability go hand in hand. Almost two decades ago, GEA introduced the first ConsiGma® continuous manufacturing (CM) system to the pharmaceutical market — a pioneering move that helped to reshape how oral solid dosage (OSD) forms are developed and produced
  2. Abselion launches AAVX and AAV9 Total Capsid Quantification Kits Ready-to-use solution for Amperia benchtop platform supports rapid, reliable quantification across a range of serotypes
  3. diaago and Peak Analysis & Automation partner to bring practical automation solutions to research laboratories Using diaago's customer-first approach with PAA’s decades of expertise in laboratory robotics, the collaboration promises to deliver solutions to streamline workflows, boost throughput and reduce bottlenecks
  4. Suncombe and Kindeva collaborate to deliver low-carbon inhalers to the NHS The partnership will develop next-generation pressurised metered-dose inhalers with low Global Warming Potential propellants, helping the NHS move closer to its Net Zero target
  5. Douglas Pharmaceuticals sets new benchmark for capsule quality with CI Precision Partnership delivers compliance confidence, efficiency gains and reduced waste

Relevant companies

See more

Upcoming event

Enhancing probiotic stability through smarter formulation and packaging strategies

18 September 2025 | Virtual See all

You may also like

Drug Delivery

Breaking barriers: enhancing the bioavailability of orally delivered TPDs

It’s been said that nothing vast enters the realm of mortals without a curse. Such is the case with targeted protein degraders (TPDs), now one of the fastest-growing frontiers in oral solid dose pharmaceuticals
Research & Development

Strategic investment by Bain Capital, Kohlberg and Mubadala fuels PCI Pharma Services’ expansion

This financial injection is expected to cement PCI’s position in the CDMO arena
Manufacturing

At BIO Show in Boston, PCI Pharma Services to provide updates on new manufacturing facility

For leading CDMO, qualification activities for plant’s state-of-the-art sterile fill-finish and lyophilisation line are underway, with GMP production commencing summer 2025
Manufacturing

Targeted protein degraders: transforming oral therapeutics

Targeted protein degraders (TPDs) are redefining modern drug discovery and development, offering a revolutionary approach to treating diseases that were once considered to be untreatable
Manufacturing

PCI Pharma Services acquires Ajinomoto Althea, makes ground on US and European expansion

PCI's acquisition of US-based sterile fill-finish CDMO Ajinomoto Althea is part of the company's overarching strategy to expand its drug delivery services within the US and Europe
Manufacturing

PCI Pharma Serives acquires US-based sterile fill-finish CDMO, Ajinomoto Althea

This acquisition will add antibody-drug conjugate (ADC) manufacturing and US-based sterile fill-finish production capabilities to PCI's portfolio
You need to be a subscriber to read this article.
Click here to find out more.
Manufacturing

The rise of targeted modalities in pharmaceutical development

Targeted modalities represent a significant evolution in drug development, reports Anshul Gupte, Vice President of Pharmaceutical Development at PCI Pharma Services. They distinguish themselves from traditional small molecules and biologics by focusing on precise mechanisms of action
Subscribe now